9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Estimated reading time: < 1 min

Condition: Carcinoma, Non-Small-Cell Lung

Estimated Enrollment: 24

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Dose-limiting toxicity of the combination of bosutinib and pemetrexed,  Maximum tolerated dose of the combination of bosutinib and pemetrexed,  Adverse events of the combination of bosutinib and pemetrexed, Anti-tumor response rate

Interventions: Bosutinib, Pemetrexed

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: January 2020

Completion Date: July 2020

Last  Posted Date: August 23, 2017

Location: UC Health, Cincinnati, Ohio, United States

Website Link: https://ClinicalTrials.gov/show/NCT03023319

Was this article helpful?
Dislike 0